- Home
- TXMD
TXMD
TherapeuticsMD Inc.
as 11-15-2024 4:00pm EST
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOCA RATON |
| Market Cap: | 17.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 17.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $3.07 | Next Earning Date: | 11-12-2024 |
| Revenue: | $1,596,000 | Revenue Growth: | -97.70% |
| Revenue Growth (this year): | 605.07% | Revenue Growth (next year): | 1.11% |
Stock Insider Trading Activity of TherapeuticsMD Inc. (TXMD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Collins Cooper C. | TXMD | Director | Aug 22 '24 | Buy | $1.73 | 4,094 | $7,099.00 | 52,016 | |
| Collins Cooper C. | TXMD | Director | Aug 21 '24 | Buy | $1.70 | 1,200 | $2,038.56 | 52,016 |
Latest TherapeuticsMD Inc. News
TXMD Breaking Stock News: Dive into TXMD Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
TherapeuticsMD Third Quarter 2024 Earnings: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)
Associated Press Finance
5 days ago
TherapeuticsMD: Q3 Earnings Snapshot
Business Wire
5 days ago
TherapeuticsMD Announces Third Quarter 2024 Financial Results
Associated Press Finance
3 months ago
TherapeuticsMD: Q2 Earnings Snapshot
Business Wire
3 months ago
TherapeuticsMD Announces Second Quarter 2024 Financial Results
Associated Press Finance
6 months ago
TherapeuticsMD: Q1 Earnings Snapshot
Business Wire
6 months ago
TherapeuticsMD Announces First Quarter 2024 Financial Results
Business Wire
8 months ago
TherapeuticsMD Announces Full Year 2023 Financial Results
Compare TXMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TXMD TherapeuticsMD Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.